GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease

Global Blood Therapeutics, Inc. has awarded approximately $450,000 to US community-based organizations and institutions as part of the company’s 2021 Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program. The program provides support to accelerate the development of sustainable access-to-care programs for people living with sickle cell disease.